This interventional trial (n=30) will assess the efficacy and safety of MDMA-assisted psychotherapy for PTSD with 2–3 oral MDMA medicine days (120 mg + 60 mg top-up typical) alongside preparatory and integration psychotherapy.
Open-label, non-randomised, single-group study of MDMA-assisted psychotherapy for PTSD. Participants receive three preparatory 1‑hour sessions, 2–3 medicine days (6–7 hours each) with supportive, client-centred psychotherapy during dosing, and sets of integration sessions after each medicine day.
MDMA is administered orally in capsules by the treating psychiatrist; typical dosing follows MAPS protocols (120 mg with 60 mg top-up at ~2 hours; 80 mg + 40 mg top-up if needed). Adverse events are recorded and reported to HREC and the TGA; psychometric measures administered pre- and post-treatment.
Open-label, single-group MDMA-assisted psychotherapy with 2–3 medicine days interspersed with preparation and integration sessions.
Typical regimen 120 mg with 60 mg top-up at ~2 hours; lower option 80 mg + 40 mg top-up if not tolerated; dosing tailored by treating psychiatrist.